// App-Quantinova.ai

4531 : Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC) The JAVELIN Renal 101 experience.

Researchers

Presenter

  • Renee Maria Saliby

Principal Investigators

  • Tejas Jammihal

  • Chris Labaki

  • Wanling Xie

  • Robert J. Motzer

  • Thomas Powles

  • Brian I. Rini

  • Laurence Albiges

  • Sumanta K. Pal

  • Rana R. McKay

  • Sabina Signoretti

  • Sachet A. Shukla

  • Eliezer Mendel Van Allen

  • David A. Braun

  • Toni K. Choueiri

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Gustave Roussy, Villejuif, France

  • University of California, San Diego, La Jolla, CA

  • Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Sunitinib

  • Inlyta

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02684006

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved